Literature DB >> 20403042

Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement.

Yasuni Nakanuma1, Yoh Zen, Kenichi Harada, Motoko Sasaki, Akitaka Nonomura, Takeshi Uehara, Kenji Sano, Fukuo Kondo, Toshio Fukusato, Koichi Tsuneyama, Masahiro Ito, Kenichi Wakasa, Minoru Nomoto, Hiroshi Minato, Hironori Haga, Masayoshi Kage, Hirohisa Yano, Joji Haratake, Shinichi Aishima, Tomoyuki Masuda, Hajime Aoyama, Aya Miyakawa-Hayashino, Toshiharu Matsumoto, Hayato Sanefuji, Hidenori Ojima, Tse-Ching Chen, Eunsil Yu, Ji-Hun Kim, Young Nyun Park, Wilson Tsui.   

Abstract

Recently the authors proposed a new staging and grading system for primary biliary cirrhosis (PBC) that takes into account necroinflammatory activity and histological heterogeneity. Herein is proposed a convenient version of this system. Scores for fibrosis, bile duct loss, and chronic cholestasis were combined for staging: stage 1, total score of 0; stage 2, score 1-3; stage 3, score 4-6; and stage 4, score 7-9. Cholangitis activity (CA) and hepatitis activity (HA) were graded as CA0-3, and HA0-3, respectively. Analysis of interobserver agreement was then conducted. Digital images of 62 needle liver biopsy specimens of PBC were recorded as virtual slides on DVDs that were sent to 28 pathologists, including five located overseas. All participants were able to apply this version in all 62 cases. For staging, kappa was 0.385 (fair agreement) and the concordance rate was 63.9%. For necroinflammatory activity, the kappa and concordance rate were 0.110 (slight agreement) and 36.9% for CA, and 0.197 (slight agreement) and 47% for HA, respectively. In conclusion, this new staging and grading system for PBC seems to be more convenient and practical than those used at present, but more instruction and guidance are recommended for the grading of necroinflammatory activity in practice.

Entities:  

Mesh:

Year:  2010        PMID: 20403042     DOI: 10.1111/j.1440-1827.2009.02500.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  29 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  On beyond staging and grading: Liver biopsy evaluation in a posttreatment world.

Authors:  David E Kleiner
Journal:  Hepatology       Date:  2017-03-30       Impact factor: 17.425

4.  The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis.

Authors:  S Shimoda; K Tsuneyama; K Kikuchi; K Harada; Y Nakanuma; M Nakamura; H Ishibashi; S Hisamoto; H Niiro; P S C Leung; A A Ansari; M E Gershwin; K Akashi
Journal:  Clin Exp Immunol       Date:  2012-06       Impact factor: 4.330

5.  RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.

Authors:  Yan-Li Hao; Zhao-Lian Bian; Lin-Ling Ju; Yuan Liu; Gang Qin
Journal:  Dig Dis Sci       Date:  2019-08-03       Impact factor: 3.199

6.  Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis.

Authors:  Motoko Sasaki; Yasuni Nakanuma
Journal:  Hepat Res Treat       Date:  2010-11-04

7.  The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases.

Authors:  Kazumichi Abe; Atsushi Takahashi; Yoshihiro Nozawa; Hiromichi Imaizumi; Manabu Hayashi; Ken Okai; Yukiko Kanno; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2014-06-27       Impact factor: 2.309

8.  Clinicopathological significance of serum fractalkine in primary biliary cirrhosis.

Authors:  Kenichi Harada; Yuko Kakuda; Minoru Nakamura; Shinji Shimoda; Yasuni Nakanuma
Journal:  Dig Dis Sci       Date:  2013-06-14       Impact factor: 3.199

9.  Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis.

Authors:  Manabu Hayashi; Kazumichi Abe; Masashi Fujita; Ken Okai; Atsushi Takahashi; Yoshihiro Nozawa; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2018-01-29       Impact factor: 2.309

10.  Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis.

Authors:  Mio Kobayashi; Yuko Kakuda; Kenichi Harada; Yasunori Sato; Motoko Sasaki; Hiroko Ikeda; Mitsuhiro Terada; Munenori Mukai; Shuichi Kaneko; Yasuni Nakanuma
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.